The U.S. Food and Drug Administration (FDA) is spearheading a transformative shift in preclinical drug safety testing through a comprehensive roadmap aimed at reducing and ultimately replacing animal studies with scientifically validated New Approach Methodologies (NAMs) (Fig.1). This shift, reinforced by the FDA Modernization Act 2.0 (2022), is motivated by growing scientific evidence, ethical concerns, and the economic burden of animal-based research. NAMs leverage human-relevant platforms such as organ-on-a-chip systems, advanced computational modeling, and innovative in vitro assays. The transition begins with monoclonal antibodies (mAbs), a class of therapeutics for which traditional animal models frequently fail to predict human responses, and will expand to include other biologics and chemical entities. This essay outlines the FDA’s key recommendations, strategies for NAM development and validation, their scientific rationale and advantages, and real-world applications, supported by illustrative case studies.

 

Fig. 1: The FDA’s New Approach Methodologies (NAMs) to Replace Animal Testing

 

The FDA New Approach Methodologies (NAMs) to Replace Animal Studies

 

Scientific Rationale for Phasing Out Animal Testing

For decades, animal testing has been the foundation of preclinical drug development, used to evaluate safety, pharmacokinetics, and preliminary efficacy before human trials. However, mounting evidence shows that animal models often fail to predict human outcomes accurately. More than 90% of drug candidates deemed safe and effective in animals ultimately fail in clinical trials, primarily due to unforeseen safety issues or lack of efficacy in humans. This high failure rate underscores a critical limitation: biological and physiological differences between humans and commonly used animal species, such as rodents and non-human primates, undermine the translatability of preclinical results.

Monoclonal antibodies (mAbs), which target specific human immune components, exemplify this disconnect. These biologics can elicit immune responses in animals that are irrelevant, or absent in humans, leading to misleading pharmacokinetic (PK) and toxicity data. The structural and regulatory differences in animal versus human immune systems often generate false-negative or false-positive safety signals.

The case of TGN1412, an anti-CD28 superagonist mAb, highlights the dangers of overreliance on animal data. Despite passing all preclinical toxicity studies in cynomolgus monkeys, the drug triggered life-threatening cytokine release syndrome in human volunteers within hours of administration. All participants required intensive care for severe systemic inflammation. Subsequent analyses revealed that the animal models failed to capture the intricacies of the human immune response. This event illustrated the urgent need for more predictive, human-relevant testing platforms.

Beyond immunology, discrepancies in metabolism, receptor expression, gene regulation, and disease progression further limit the applicability of animal models in fields such as oncology, neurodegeneration, and inflammatory diseases. These scientific shortcomings, coupled with ethical and economic concerns, have led to a reevaluation of animal testing. NAMs offer a more reliable, efficient, and humane alternative, using human-derived systems and computational models to enhance clinical translation, reduce late-stage drug failures, and deliver safer, more effective therapies.

FDA’s Requirements and Recommendations for Reducing Animal Testing

To modernize preclinical safety testing, the FDA has outlined strategic priorities for reducing reliance on animal studies. A key initiative is minimizing the use of long-term primate studies in mAb development, particularly when short-term studies and NAM data indicate no significant safety risks. The FDA also encourages sponsors to submit NAM data alongside traditional animal results, fostering comparative analysis and regulatory confidence. To streamline the regulatory process, the FDA supports the use of international human and animal toxicity data to avoid redundant testing.

Moreover, the agency advocates integrating predictive computational tools, such as physiologically based pharmacokinetic (PBPK) models and AI-driven risk assessments, into Investigational New Drug (IND) and Biologics License Application (BLA) submissions. Open-access databases, such as the forthcoming CAMERA (Collection of Alternative Methods for Regulatory Application), will centralize NAM performance metrics and toxicity data to enhance transparency, collaboration, and data reuse across the regulatory landscape.

 

Fig. 2: The FDA Requirements and Recommendations to Replace Animal Studies

The FDA New Approach Methodologies (NAMs) to Replace Animal Studies

 

New Approach Methodologies (NAMs)

Organ-on-a-Chip and Microphysiological Systems (MPS)

Organoids and microphysiological systems (MPS) replicate human tissue structure/function using 3D cell cultures, microfluidics, and mechanical forces. Organoids mimic organ architecture, while MPS (e.g., Liver-Chip) integrate perfusion and multi-cell co-cultures to model metabolism/drug responses. These systems outperform animal models in human-specific toxicity prediction, exemplified by FDA-recognized Liver-Chips accurately detecting hepatotoxins. For monoclonal antibodies, MPS assess off-target effects via immune-cell-integrated platforms (e.g., cytokine release in Liver-Chips) or cardiac microtissues monitoring arrhythmias. Post-TGN1412, human cytokine release assays using blood-on-a-chip systems now flag immunotoxicity missed in animals. Multi-organ MPS platforms model systemic interactions (e.g., liver-tumor-immune networks), enhancing clinical relevance by preserving human physiology.

The FDA promotes validated, human-based MPS to assess organ-specific toxicity, immunogenicity, and pharmacodynamics. These systems are especially suited for evaluating mAbs that target human-specific pathways, such as immune checkpoints. Development efforts are supported by multi-agency collaborations under the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), which standardizes protocols and ensures cross-laboratory reproducibility.

One success is the Innovative Science and Technology for Advancing New Drugs (ISTAND) pilot program, which qualified the Human Liver-Chip for evaluating drug-induced liver injury (DILI). MPS replicate human tissue architecture and cellular signaling, outperforming animal models in predictive power. For example, the Liver-Chip identified 87% of hepatotoxic drugs in a validation study, surpassing the accuracy of animal tests. The TGN1412 incident also spurred the development of human-based cytokine release assays (CRAs), which are now standard in preclinical immunotoxicity evaluation.

In Silico Tools and Computational Modeling

The FDA supports the use of artificial intelligence (AI), machine learning (ML), and PBPK models to predict immunogenicity, toxicity, and pharmacokinetics. These tools can be validated using retrospective analyses of historical datasets, such as those from the Tox21 initiative. Open-access resources like the Integrated Chemical Environment (ICE) further aid model development and validation.

In silico methods offer rapid and cost-effective alternatives to animal studies. For instance, AbImmPred predicts antibody immunogenicity from amino acid sequences within minutes. PBPK models simulate drug metabolism in human physiology, bypassing interspecies variability. CATMoS, an AI model integrating animal and human data, achieved 85% accuracy in predicting acute toxicity.

Ex Vivo Human Tissues

The FDA encourages the use of donated human tissue slices, such as liver and heart samples, for localized toxicity testing. Ethical tissue sourcing and viability are supported through partnerships with organ procurement organizations. These tissues may also be combined with MPS for multi-organ interaction studies. Unlike standard cell cultures, ex vivo systems retain native metabolic and cellular architecture. For example, human heart slices have revealed cardiotoxic effects of kinase inhibitors that were not detected in rodent models.

High-Throughput Cell-Based Screening

To replace multi-species animal testing, the FDA promotes robotic high-throughput screening using human iPSC-derived cells. Development efforts focus on creating ethnically diverse cell panels to capture population-level variability. NIH-funded initiatives such as Complement-ARIE support the advancement of combinatorial NAMs. High-throughput platforms can screen thousands of compounds for off-target effects within weeks. The Tox21 program has screened over 10,000 chemicals, identifying endocrine disruptors with greater specificity than animal models.

Microdosing and Human Imaging

Microdosing studies, combined with PET imaging, allow the direct assessment of biodistribution in human subjects. Validation occurs via Phase 0 trials and existing infrastructure such as the VA system. This approach enables early human data collection with minimal risk. In oncology, microdosing has revealed human-specific tumor uptake patterns for antibody-drug conjugates, informing clinical trial design.

FDA Implementation Strategies

To accelerate NAM adoption, the FDA has proposed a multipronged implementation strategy. Regulatory flexibility is essential: new guidance will permit validated NAMs to replace specific animal tests, including chronic toxicity studies. Pilot programs will explore waiving animal studies for mAbs targeting human-exclusive receptors. Through ICCVAM, the FDA will continue cross-agency validation projects, such as NIH-funded Liver-Chip studies, and will launch the CAMERA database in 2025.

Incentives include expedited review pathways for NAM-based submissions and public recognition for milestone approvals that exclude animal testing. These initiatives aim to shift industry norms and establish NAMs as the new standard in safety evaluation.

Validation and Standardization

Regulatory acceptance of NAMs depends on robust validation and standardization. Retrospective studies comparing NAM predictions to clinical outcomes will establish predictive accuracy. Prospective parallel trials can further validate performance against animal models. Standardized protocols, reproducible across multiple laboratories, are essential. NAMs should be qualified through FDA programs such as ISTAND or the Drug Development Tool (DDT) pathway, which define acceptable contexts of use.

Policy and Global Harmonization

The FDA is also advancing policy reforms and international alignment to support global NAM adoption. This includes revising ICH guidelines to harmonize regulatory expectations. Public-private partnerships will drive NAM co-development, pooling expertise across sectors. Legislative incentives such as fast-track reviews and reduced submission burdens are under consideration. Internally, the FDA is investing in educational programs to equip staff with the skills to evaluate NAM data and support a modern regulatory framework.

Conclusion

The FDA’s roadmap marks a foundational shift toward human-relevant, scientifically robust drug development. Through organ-on-chip platforms, in silico models, and ex vivo assays, the agency aims to enhance the predictive accuracy of preclinical safety testing while reducing the ethical and financial burdens of animal research. Case studies such as the Liver-Chip and TGN1412 highlight both the shortcomings of animal models and the promise of NAMs. Continued regulatory flexibility, cross-agency collaboration, and international harmonization will be key to ensuring the successful integration of NAMs and positioning the U.S. at the forefront of 21st-century regulatory science.

Reference

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)